Adaptive vs Conventional Deep Brain Stimulation of the Subthalamic Nucleus for Treatment of Parkinson's Disease: A Multicenter Retrospective Study
Summary
This multicenter retrospective study compared adaptive DBS with conventional DBS in 62 Parkinson's disease patients over one year. The adaptive DBS group showed significantly greater improvements in activities of daily living, motor complications, quality of life, and levodopa-equivalent dose reduction. The system recorded clear STN-beta signals usable as biomarkers for adaptive stimulation.
Why it matters
Adaptive DBS represents the next generation of neuromodulation therapy, potentially offering better outcomes with less energy consumption. This real-world multicenter evidence supports broader clinical adoption and reimbursement for adaptive systems, impacting companies like Medtronic and Boston Scientific.
Want the full NeurotechMag Pro intelligence database?
Access 800+ papers, trials, patents, funding rounds and news items — updated daily.
Start free trial